https://www.thebodypro.com/category/tenofovir-tdf-viread/tag/id-week

The Latest

Promo Image

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older Img

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.

Long-Term Tenofovir Use Associated With Higher Rates of Kidney Problems Img

Long-Term Tenofovir Use Associated With Higher Rates of Kidney Problems

Renal dysfunction was more likely in patients who had taken tenofovir (Truvada, TDF) longer, were older, or also had diabetes or hypertension, according to a study presented at IDWeek 2014.

Promo Image

What 2014 Development Has the Biggest Impact on HIV Care?

Each year we see new developments in HIV that improve the lives of those living with the disease and make it easier for providers to care for patients. We asked some of the leading experts what development this year they thought would have the biggest …

Promo Image

What's Hot in HIV Treatment

Here’s a recap of the biggest developments in HIV treatment over the past year, as well as a look at what’s to come.